AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data
Executive Summary
The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.
You may also be interested in...
Lynparza On Track For Broad Frontline Use In Prostate Cancer
AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.
Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut
The company plans to start in Germany with an outcomes-based payment model. But while a US FDA nod seems likely, analysts have been more cautious about calling US approval a done deal.